# OnCo record xaluritamig (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/xaluritamig/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "xaluritamig" ;
  schema:name "Xaluritamig"@en ;
  schema:description "Xaluritamig is Amgen's T-cell engager for prostate cancer, now in two phase 3 trials, aiming to do for prostate cancer what tarlatamab did for small-cell lung cancer."@en ;
  schema:url <https://onco.cc/drugs/xaluritamig/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06691984>, <https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS5144> ;
  onco:status "phase-3" ;
  onco:modality "Bispecific T-cell engager (STEAP1×CD3, XmAb 2+1)" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/steap1/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/psa50/> ;
  onco:trials <https://onco.cc/trials/xalute/>, <https://onco.cc/trials/nct07213674/> .